The tyranny of non-inferiority trials

Opportunities to decrease the toxicity and cost of approved treatment regimens with lower dose, less frequent, or shorter duration alternative regimens have been limited by the perception that alternatives must be non-inferior to approved regimens. Non-inferiority trials are large and expensive to d...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 25; no. 10; pp. e520 - e525
Main Authors:	Tannock, Ian F, Buyse, Marc, De Backer, Mickael, Earl, Helena, Goldstein, Daniel A, Ratain, Mark J, Saltz, Leonard B, Sonke, Gabe S, Strohbehn, Garth W
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.10.2024 Elsevier Limited
Subjects:	Adjuvants Cancer therapies Chemotherapy Clinical trials Clinical Trials as Topic Cost-Benefit Analysis Drug dosages Equivalence Trials as Topic FDA approval Hematology, Oncology, and Palliative Medicine Humans Meta-analysis Neoplasms - drug therapy Patient-centered care Pharmaceutical industry Research Design Schedules Toxicity United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!